Skip to content
Screener

Supernus Pharmaceuticals SUPN Business Segments — Selling expenses

Similar metrics at other companies

ARH
ARHSReportable Segment — Selling expenses
$45.85M+20.8%
KRT
KRTReportable Segment — Selling expenses
$2.46M+28.9%
Beyond Meat logo
BYNDReporting Segment — Selling expenses
$6.79M+0.7%
Aramark logo
ARMKFSS International — Selling expenses
$7.6M+38.2%
Kadant logo
KAIFlow Control — Selling expenses
$15.19M+2.8%
Kadant logo
KAIIndustrial Processing — Selling expenses
$13.88M+36.4%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+14.3%
Enterprise value$2.57B+13.6%
P/S3.5×-0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingExpense.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total revenues$207,705$149,824
Less: Significant segment expenses:
Cost of revenues23,39115,763
Selling expenses66,27842,614
Marketing expenses20,69720,664
General and administrative expenses38,19826,666
Research and development expenses
External development program expenses:

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's business segments — selling expenses?
Supernus Pharmaceuticals (SUPN) reported business segments — selling expenses of $66.28M in Q1 2026.
How has Supernus Pharmaceuticals's business segments — selling expenses changed year-over-year?
Supernus Pharmaceuticals's business segments — selling expenses increased by 55.5% year-over-year, from $42.61M to $66.28M.
What is the long-term trend for Supernus Pharmaceuticals's business segments — selling expenses?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — selling expenses has grown at a 12.5% compound annual growth rate (CAGR), from $147.29M to $209.7M.
What does business segments — selling expenses mean?
Captures the costs incurred by the sales force to promote and distribute pharmaceutical products to healthcare providers. These expenditures are critical for driving market penetration and maintaining physician awareness of the company's therapeutic offerings.

Ask your AI about Supernus Pharmaceuticals's business segments — selling expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude